# Jenscare

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jenscare

- Industry: Medical Devices & Equipment
- Headquarters: Ningbo, China
- Website: www.jenscare.com
- Total disclosed funding: $1.6M
- Latest round: Series B (May 28, 2021)
- Investors on record: 13

## About

Founded in 2011 and based in Hangzhou, China, Ningbo Jenscare Biotechnology Co., Ltd. doing business named Jenscare, is a healthcare equipment company that provides interventional products for structural heart diseases. In 2014, it started to R&D of Ken-Valve, AnchorValve, Lux-Valve, and MitraPatch. Ken-Valve and Lux-Valve completed the implantation in the human subject in 2018. And Lux-Valve started a clinical trial in 2020, and completed the subject enrollment of the confirmatory clinical trial in 2021. Also, Ken-Valve completed the subject enrollment of the confirmatory clinical trial in 2022. Jenscare was listed on Hong Kong Stock Exchange under the number 09877 in October 2022.

Jenscare provides valves for heart valve interventional therapy. Lux-Valve is a transcatheter tricuspid valve replacement system for patients with tricuspid regurgitation. Ken-Valve can be used to treat aortic regurgitation and aortic stenosis systems.

## Funding rounds

- Series B, May 28, 2021 — GP Capital, China Asset Management, China International Capital Corporation, Primavera Capital Group, PICC Capital Equity Investment, Cormorant Asset Management, Forebright Capital Management, CD Capital, Proxima Ventures, China Life Capital, FutureX Capital, GL Ventures, ABC International Capital
- Series A, Feb 18, 2019 — Proxima Ventures
- Series A, May 4, 2018, $1.6M — CD Capital

## Investors

- CD Capital — Series A, Series B
- Proxima Ventures (https://capitalatlas.ai/funds/proxima-ventures) — Series A, Series B
- GP Capital (https://capitalatlas.ai/funds/gp-capital) — Series B
- China Asset Management — Series B
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series B
- Primavera Capital Group (https://capitalatlas.ai/funds/primavera-capital-group) — Series B
- PICC Capital Equity Investment (https://capitalatlas.ai/funds/picc-capital-equity-investment) — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Forebright Capital Management (https://capitalatlas.ai/funds/forebright-capital-management) — Series B
- China Life Capital — Series B
- FutureX Capital (https://capitalatlas.ai/funds/futurex-capital) — Series B
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series B
- ABC International Capital (https://capitalatlas.ai/funds/abc-international-capital) — Series B